Shai Shimony

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 58

Top Topics

Combination Therapy

Acute Myeloid Leukemia

Systematic Review

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Jan Philipp Bewersdorf, Shai Shimony, Rory Michael Shallis, Yiwen Liu, Guillaume Berton, Eva Johanna Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, Rebecca Bystrom, R Coleman Lindsley, Evan C Chen, Jorge Miguel Ramos Perez, Anthony S Stein, Vinod A Pullarkat, Ibrahim Aldoss, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Sylvain Garciaz, Brian J Ball, Maximilian Stahl
Intensive Induction Chemotherapy versus Hypomethylating Agents in Combination with Venetoclax in NPM1-mutant AML. Blood advances (2024)
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, Yiwen Liu, Guillaume Berton, Eva J Schaefer, Amer M Zeidan, Aaron Goldberg, Eytan Stein, Guido Marcucci, Rebecca P Bystrom, R Coleman Lindsley, Evan C Chen, Jorge Ramos, Anthony Stein, Vinod A Pullarkat, Ibrahim Aldoss, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Sylvain Garciaz, Brian J Ball, Maximilian Stahl
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study. American journal of hematology 99 (8) (2024)
Qingyu Luo, Evangeline G Raulston, Miguel A Prado, Xiaowei Wu, Kira Gritsman, Karley S Whalen, Kezhi Yan, Christopher A G Booth, Ran Xu, Peter van Galen, John G Doench, Shai Shimony, Henry W Long, Donna S Neuberg, Joao A Paulo, Andrew A Lane
Targetable leukaemia dependency on noncanonical PI3Kγ signalling. Nature (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 38 (4) (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia (2024)
Qingyu Luo, Evangeline G Raulston, Miguel A Prado, Xiaowei Wu, Kira Gritsman, Karley S Whalen, Kezhi Yan, Christopher A G Booth, Ran Xu, Peter van Galen, John G Doench, Shai Shimony, Henry W Long, Donna S Neuberg, Joao A Paulo, Andrew A Lane
Targetable leukaemia dependency on noncanonical PI3Kγ signalling. Nature 630 (8015) (2024)
Qingyu Luo, Evangeline G Raulston, Miguel A Prado, Xiaowei Wu, Kira Gritsman, Karley S Whalen, Kezhi Yan, Christopher A G Booth, Ran Xu, Peter van Galen, John G Doench, Shai Shimony, Henry W Long, Donna S Neuberg, Joao A Paulo, Andrew A Lane
Targetable leukaemia dependency on noncanonical PI3Kγ signalling. Nature 630 (8015) (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia 38 (3) (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38 (7) (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38 (7) (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38 (7) (2024)
Shai Shimony, Julia Keating, Christopher J Fay, Marlise R Luskin, Donna S Neuberg, Nicole R LeBoeuf, Andrew A Lane
Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival. Blood advances 8 (11) (2024)
Johann-Christoph Jann, Christopher B Hergott, Marisa Winkler, Yiwen Liu, Benjamin Braun, Anne Charles, Kevin M Copson, Shougat Barua, Manja Meggendorfer, Niroshan Nadarajah, Shai Shimony, Eric S Winer, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Jacqueline S Garcia, Torsten Haferlach, R Coleman Lindsley, Marlise R Luskin, Maximilian Stahl, Zuzana Tothova
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia 38 (9) (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia 38 (3) (2024)
Shai Shimony, Julia Keating, Christopher J Fay, Marlise R Luskin, Donna S Neuberg, Nicole R LeBoeuf, Andrew A Lane
Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival. Blood advances 8 (11) (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia 38 (3) (2024)
Shai Shimony, Julia Keating, Christopher J Fay, Marlise R Luskin, Donna S Neuberg, Nicole R LeBoeuf, Andrew A Lane
Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival. Blood advances 8 (11) (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 38 (4) (2024)
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, Yiwen Liu, Guillaume Berton, Eva J Schaefer, Amer M Zeidan, Aaron Goldberg, Eytan Stein, Guido Marcucci, Rebecca P Bystrom, R Coleman Lindsley, Evan C Chen, Jorge Ramos, Anthony Stein, Vinod A Pullarkat, Ibrahim Aldoss, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Sylvain Garciaz, Brian J Ball, Maximilian Stahl
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study. American journal of hematology (2024)
Shai Shimony, Jan Philipp Bewersdorf, Rory Michael Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Evan C Chen, Jorge Ramos Perez, Anthony Stein, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Brian Ball, Maximilian Stahl
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML. Leukemia 38 (4) (2024)
Shai Shimony, Julia H Keating, Christopher J Fay, Marlise R Luskin, Donna S Neuberg, Nicole R LeBoeuf, Andrew A Lane
Organ Involvement in Adults with BPDCN is Associated with Sun Exposure History, TET2 and RAS Mutations, and Survival. Blood advances (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38 (7) (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia 38 (3) (2024)
Qingyu Luo, Evangeline G Raulston, Miguel A Prado, Xiaowei Wu, Kira Gritsman, Karley S Whalen, Kezhi Yan, Christopher A G Booth, Ran Xu, Peter van Galen, John G Doench, Shai Shimony, Henry W Long, Donna S Neuberg, Joao A Paulo, Andrew A Lane
Targetable leukaemia dependency on noncanonical PI3Kγ signalling. Nature 630 (8015) (2024)
Qingyu Luo, Evangeline G Raulston, Miguel A Prado, Xiaowei Wu, Kira Gritsman, Karley S Whalen, Kezhi Yan, Christopher A G Booth, Ran Xu, Peter van Galen, John G Doench, Shai Shimony, Henry W Long, Donna S Neuberg, Joao A Paulo, Andrew A Lane
Targetable leukaemia dependency on noncanonical PI3Kγ signalling. Nature (2024)
Eitan Kugler, Inbar Cohen, Irina Amitai, Ron Ram, Avraham Frisch, Boaz Nachmias, Jonathan Canaani, Yakir Moshe, Baher Krayem, Shlomzion Aumann, Israel Henig, Vladimir Vainstein, Liat Shargian-Alon, Chezi Ganzel, Moshe Yeshurun, Itay Levi, Pia Raanani, Luiza Akria, Yishai Ofran, Shai Shimony, Ofir Wolach
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia. British journal of haematology (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia (2024)
Yannis K Valtis, Yael Flamand, Shai Shimony, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia 38 (3) (2024)
Johann-Christoph Jann, Christopher B Hergott, Marisa Winkler, Yiwen Liu, Benjamin Braun, Anne Charles, Kevin M Copson, Shougat Barua, Manja Meggendorfer, Niroshan Nadarajah, Shai Shimony, Eric S Winer, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Jacqueline S Garcia, Torsten Haferlach, R Coleman Lindsley, Marlise R Luskin, Maximilian Stahl, Zuzana Tothova
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia 38 (9) (2024)
Shai Shimony, Jacqueline S Garcia, Julia Keating, Evan C Chen, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, Richard M Stone, R Coleman Lindsley
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia 38 (7) (2024)
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, Yiwen Liu, Guillaume Berton, Eva J Schaefer, Amer M Zeidan, Aaron Goldberg, Eytan Stein, Guido Marcucci, Rebecca P Bystrom, R Coleman Lindsley, Evan C Chen, Jorge Ramos, Anthony Stein, Vinod A Pullarkat, Ibrahim Aldoss, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Sylvain Garciaz, Brian J Ball, Maximilian Stahl
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study. American journal of hematology 99 (8) (2024)
Shai Shimony, Julia Keating, Christopher J Fay, Marlise R Luskin, Donna S Neuberg, Nicole R LeBoeuf, Andrew A Lane
Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival. Blood advances 8 (11) (2024)
Johann-Christoph Jann, Christopher B Hergott, Marisa Winkler, Yiwen Liu, Benjamin Braun, Anne Charles, Kevin M Copson, Shougat Barua, Manja Meggendorfer, Niroshan Nadarajah, Shai Shimony, Eric S Winer, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Jacqueline S Garcia, Torsten Haferlach, R Coleman Lindsley, Marlise R Luskin, Maximilian Stahl, Zuzana Tothova
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia 38 (9) (2024)
Qingyu Luo, Evangeline G Raulston, Miguel A Prado, Xiaowei Wu, Kira Gritsman, Karley S Whalen, Kezhi Yan, Christopher A G Booth, Ran Xu, Peter van Galen, John G Doench, Shai Shimony, Henry W Long, Donna S Neuberg, Joao A Paulo, Andrew A Lane
Targetable leukaemia dependency on noncanonical PI3Kγ signalling. Nature (2024)
Jan Philipp Bewersdorf, Shai Shimony, Rory M Shallis, Yiwen Liu, Guillaume Berton, Eva J Schaefer, Amer M Zeidan, Aaron Goldberg, Eytan Stein, Guido Marcucci, Rebecca P Bystrom, R Coleman Lindsley, Evan C Chen, Jorge Ramos, Anthony Stein, Vinod A Pullarkat, Ibrahim Aldoss, Daniel J DeAngelo, Donna S Neuberg, Richard M Stone, Sylvain Garciaz, Brian J Ball, Maximilian Stahl
Combination therapy with hypomethylating agents and venetoclax versus intensive induction chemotherapy in IDH1- or IDH2-mutant newly diagnosed acute myeloid leukemia-A multicenter cohort study. American journal of hematology 99 (8) (2024)
Qingyu Luo, Evangeline G Raulston, Miguel A Prado, Xiaowei Wu, Kira Gritsman, Karley S Whalen, Kezhi Yan, Christopher A G Booth, Ran Xu, Peter van Galen, John G Doench, Shai Shimony, Henry W Long, Donna S Neuberg, Joao A Paulo, Andrew A Lane
Targetable leukaemia dependency on noncanonical PI3Kγ signalling. Nature (2024)
Johann-Christoph Jann, Christopher B Hergott, Marisa Winkler, Yiwen Liu, Benjamin Braun, Anne Charles, Kevin M Copson, Shougat Barua, Manja Meggendorfer, Niroshan Nadarajah, Shai Shimony, Eric S Winer, Martha Wadleigh, Richard M Stone, Daniel J DeAngelo, Jacqueline S Garcia, Torsten Haferlach, R Coleman Lindsley, Marlise R Luskin, Maximilian Stahl, Zuzana Tothova
Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia (2024)
Shai Shimony, Maximilian Stahl, Richard M Stone
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. American journal of hematology 98 (3) (2023)
Shai Shimony, Marlise R Luskin
Unraveling KMT2A-rearranged ALL. Blood 142 (21) (2023)
Shai Shimony, Geoffrey G Fell, Evan C Chen, Harrison K Tsai, Martha Wadleigh, Eric S Winer, Jacqueline S Garcia, Marlise R Luskin, Maximilian Stahl, Donna S Neuberg, Daniel J DeAngelo, R Coleman Lindsley, Richard M Stone
FLT3-ITD does not predict inferior prognosis in acute myeloid leukemia patients age ≥60 years. Blood advances (2023)
Shai Shimony, Yael Flamand, Yannis K Valtis, Andrew E Place, Lewis B Silverman, Lynda M Vrooman, Andrew M Brunner, Stephen E Sallan, Richard M Stone, Martha Wadleigh, Donna S Neuberg, Daniel J DeAngelo, Marlise R Luskin
Effect of BMI on Toxicities and Survival Among Adolescents and Young Adults Treated on DFCI Consortium ALL Trials. Blood advances (2023)
Shai Shimony, Maximilian Stahl, Richard M Stone
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification and management. American journal of hematology (2023)
Shai Shimony, Maximilian Stahl, Richard M Stone
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. American journal of hematology 98 (3) (2023)
Shai Shimony, Maximilian Stahl, Richard M Stone
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. American journal of hematology 98 (3) (2023)
Shai Shimony, Maximilian Stahl, Richard M Stone
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. American journal of hematology (2023)
Shai Shimony, Maximilian Stahl, Richard M Stone
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. American journal of hematology 98 (3) (2023)
Shai Shimony, Daniel J DeAngelo, Marlise R Luskin
Nelarabine: When, Where and How to Use it When Treating T-cell Acute Lymphoblastic Leukemia. Blood advances (2023)
Shai Shimony, Maximilian Stahl, Richard M Stone
Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. American journal of hematology 98 (3) (2023)
Shai Shimony, Yiwen Liu, Yannis K Valtis, Jonathan D Paolino, Andrew E Place, Andrew M Brunner, Lachelle Dawn Weeks, Lewis B Silverman, Lynda M Vrooman, Donna Neuberg, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Nelarabine Combination Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Lymphoma/Leukemia. Blood advances (2022)
Shai Shimony, Jonathan Canaani, Eitan Kugler, Boaz Nachmias, Ron Ram, Israel Henig, Avraham Frisch, Chezi Ganzel, Vladimir Vainstein, Yakir Moshe, Shlomzion Aumann, Moshe Yeshurun, Yishai Ofran, Pia Raanani, Ofir Wolach
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis. Annals of hematology 101 (9) (2022)
Shai Shimony, Yiwen Liu, Yannis K Valtis, Jonathan D Paolino, Andrew E Place, Andrew M Brunner, Lachelle Dawn Weeks, Lewis B Silverman, Lynda M Vrooman, Donna Neuberg, Richard M Stone, Daniel J DeAngelo, Marlise R Luskin
Nelarabine Combination Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Lymphoma/Leukemia. Blood advances (2022)
Shai Shimony, Moshe Yeshurun, Ofir Wolach, Ron Ram, Uri Rozovski, Liat Shargian-Alon, Tsila Zukerman, Odelia Amit, Yael Bar-On, Baher Krayem, Batya Avni, Galit Peretz, Pia Raanani, Oren Pasvolsky
Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study. Leukemia & lymphoma 62 (10) (2021)
Oren Pasvolsky, Shai Shimony, Moshe Yeshurun, Liat Shargian-Alon, Ofir Wolach, Pia Raanani, Anat Gafter-Gvili, Ronit Gurion
Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis. Acta oncologica (Stockholm, Sweden) 60 (10) (2021)
Shai Shimony, Einat Bar-Sever, Tamar Berger, Gilad Itchaki, Ronit Gurion, Moshe Yeshurun, Meir Lahav, Pia Raanani, Ofir Wolach
Late onset neutropenia after rituximab and obinutuzumab treatment - characteristics of a class-effect toxicity. Leukemia & lymphoma 62 (12) (2021)
Irina Amitai, Uri Rozovski, Reem El-Saleh, Shai Shimony, Daniel Shepshelovich, Benaya Rozen-Zvi, Pia Raanani, Anat Gafter-Gvili, Ronit Gurion
Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies. Hematological oncology 38 (4) (2020)
Shai Shimony, Netanel A Horowitz, Elena Ribakovsky, Uri Rozovski, Abraham Avigdor, Keren Zloto, Tamar Berger, Irit Avivi, Chava Perry, Uri Abadi, Pia Raanani, Anat Gafter-Gvili, Ronit Gurion
Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study. Hematological oncology 37 (5) (2019)